Pigmented villonodular synovitis: Potential pitfall on oncologic 18F-FDG PET/CT

Stephen Broski, Nathan M. Murdoch, John A. Skinner, Doris E. Wenger

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose This study evaluated the semiquantitative and qualitative appearance of pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCTTS) on 18F-FDG PET/CT. Patients and Methods An institutional review board-approved retrospective review was performed for patients diagnosed with GCTTS, focal PVNS, or diffuse PVNS who underwent PET/CT from 2003 to 2013. SUVmax and SUVmax/SUVmean of the liver (SUVr) were determined for each lesion on all available PET/CTs. Relevant conventional imaging and patient records were reviewed. Results Fourteen patients (mean [SD] age, 52.8 [14.0] years; range, 26-74 years) were identified, 6 with 2 or more PET/CT examinations. The mean (SD) SUVmax and SUVr of all lesions were 8.7 (3.4; range, 4.0-14.5) and 3.9 (1.7; range, 2.0-7.1), respectively. There was no difference of the mean (SD) SUVmax (P = 0.10) or SUVr (P = 0.11) between focal PVNS (6.8 [3.0], 3.3 [1.9]), GCTTS (9.1 [3.0], 4.0 [1.2]), or diffuse PVNS (14.5, 7.1) subtypes. Of 29 comparison PET/CTs in 6 patients, 17 were performed after nontargeted chemotherapy and 12 without antecedent therapy. Significant SUVr fluctuations (>25%) occurred in 11 cases; no correlation existed between SUVr change and presence or absence of chemotherapy. Conclusions Pigmented villonodular synovitis and GCTTS can be intensely hypermetabolic, mimicking musculoskeletal metastases on 18F-FDG PET/CT. They may have significant SUV fluctuations, both during nontargeted chemotherapy and between treatments. The diagnosis of PVNS/GCTTS should be considered for focal intra-articular or juxta-articular FDG-avid lesions, and MRI is useful in further evaluation given the often diagnostic imaging features with this modality.

Original languageEnglish (US)
Pages (from-to)e24-e31
JournalClinical Nuclear Medicine
Volume41
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Pigmented Villonodular Synovitis
Fluorodeoxyglucose F18
Drug Therapy
Joints
Research Ethics Committees
Diagnostic Imaging
Giant Cell Tumor of Tendon Sheath
Neoplasm Metastasis
Liver
Therapeutics

Keywords

  • giant cell tumor of the tendon sheath
  • PET/CT
  • PVNS
  • tenosynovial giant cell tumor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Pigmented villonodular synovitis : Potential pitfall on oncologic 18F-FDG PET/CT. / Broski, Stephen; Murdoch, Nathan M.; Skinner, John A.; Wenger, Doris E.

In: Clinical Nuclear Medicine, Vol. 41, No. 1, 01.01.2016, p. e24-e31.

Research output: Contribution to journalArticle

Broski, Stephen ; Murdoch, Nathan M. ; Skinner, John A. ; Wenger, Doris E. / Pigmented villonodular synovitis : Potential pitfall on oncologic 18F-FDG PET/CT. In: Clinical Nuclear Medicine. 2016 ; Vol. 41, No. 1. pp. e24-e31.
@article{a9604fccb94a43dc9032b407ab2db7dc,
title = "Pigmented villonodular synovitis: Potential pitfall on oncologic 18F-FDG PET/CT",
abstract = "Purpose This study evaluated the semiquantitative and qualitative appearance of pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCTTS) on 18F-FDG PET/CT. Patients and Methods An institutional review board-approved retrospective review was performed for patients diagnosed with GCTTS, focal PVNS, or diffuse PVNS who underwent PET/CT from 2003 to 2013. SUVmax and SUVmax/SUVmean of the liver (SUVr) were determined for each lesion on all available PET/CTs. Relevant conventional imaging and patient records were reviewed. Results Fourteen patients (mean [SD] age, 52.8 [14.0] years; range, 26-74 years) were identified, 6 with 2 or more PET/CT examinations. The mean (SD) SUVmax and SUVr of all lesions were 8.7 (3.4; range, 4.0-14.5) and 3.9 (1.7; range, 2.0-7.1), respectively. There was no difference of the mean (SD) SUVmax (P = 0.10) or SUVr (P = 0.11) between focal PVNS (6.8 [3.0], 3.3 [1.9]), GCTTS (9.1 [3.0], 4.0 [1.2]), or diffuse PVNS (14.5, 7.1) subtypes. Of 29 comparison PET/CTs in 6 patients, 17 were performed after nontargeted chemotherapy and 12 without antecedent therapy. Significant SUVr fluctuations (>25{\%}) occurred in 11 cases; no correlation existed between SUVr change and presence or absence of chemotherapy. Conclusions Pigmented villonodular synovitis and GCTTS can be intensely hypermetabolic, mimicking musculoskeletal metastases on 18F-FDG PET/CT. They may have significant SUV fluctuations, both during nontargeted chemotherapy and between treatments. The diagnosis of PVNS/GCTTS should be considered for focal intra-articular or juxta-articular FDG-avid lesions, and MRI is useful in further evaluation given the often diagnostic imaging features with this modality.",
keywords = "giant cell tumor of the tendon sheath, PET/CT, PVNS, tenosynovial giant cell tumor",
author = "Stephen Broski and Murdoch, {Nathan M.} and Skinner, {John A.} and Wenger, {Doris E.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/RLU.0000000000000893",
language = "English (US)",
volume = "41",
pages = "e24--e31",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Pigmented villonodular synovitis

T2 - Potential pitfall on oncologic 18F-FDG PET/CT

AU - Broski, Stephen

AU - Murdoch, Nathan M.

AU - Skinner, John A.

AU - Wenger, Doris E.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose This study evaluated the semiquantitative and qualitative appearance of pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCTTS) on 18F-FDG PET/CT. Patients and Methods An institutional review board-approved retrospective review was performed for patients diagnosed with GCTTS, focal PVNS, or diffuse PVNS who underwent PET/CT from 2003 to 2013. SUVmax and SUVmax/SUVmean of the liver (SUVr) were determined for each lesion on all available PET/CTs. Relevant conventional imaging and patient records were reviewed. Results Fourteen patients (mean [SD] age, 52.8 [14.0] years; range, 26-74 years) were identified, 6 with 2 or more PET/CT examinations. The mean (SD) SUVmax and SUVr of all lesions were 8.7 (3.4; range, 4.0-14.5) and 3.9 (1.7; range, 2.0-7.1), respectively. There was no difference of the mean (SD) SUVmax (P = 0.10) or SUVr (P = 0.11) between focal PVNS (6.8 [3.0], 3.3 [1.9]), GCTTS (9.1 [3.0], 4.0 [1.2]), or diffuse PVNS (14.5, 7.1) subtypes. Of 29 comparison PET/CTs in 6 patients, 17 were performed after nontargeted chemotherapy and 12 without antecedent therapy. Significant SUVr fluctuations (>25%) occurred in 11 cases; no correlation existed between SUVr change and presence or absence of chemotherapy. Conclusions Pigmented villonodular synovitis and GCTTS can be intensely hypermetabolic, mimicking musculoskeletal metastases on 18F-FDG PET/CT. They may have significant SUV fluctuations, both during nontargeted chemotherapy and between treatments. The diagnosis of PVNS/GCTTS should be considered for focal intra-articular or juxta-articular FDG-avid lesions, and MRI is useful in further evaluation given the often diagnostic imaging features with this modality.

AB - Purpose This study evaluated the semiquantitative and qualitative appearance of pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCTTS) on 18F-FDG PET/CT. Patients and Methods An institutional review board-approved retrospective review was performed for patients diagnosed with GCTTS, focal PVNS, or diffuse PVNS who underwent PET/CT from 2003 to 2013. SUVmax and SUVmax/SUVmean of the liver (SUVr) were determined for each lesion on all available PET/CTs. Relevant conventional imaging and patient records were reviewed. Results Fourteen patients (mean [SD] age, 52.8 [14.0] years; range, 26-74 years) were identified, 6 with 2 or more PET/CT examinations. The mean (SD) SUVmax and SUVr of all lesions were 8.7 (3.4; range, 4.0-14.5) and 3.9 (1.7; range, 2.0-7.1), respectively. There was no difference of the mean (SD) SUVmax (P = 0.10) or SUVr (P = 0.11) between focal PVNS (6.8 [3.0], 3.3 [1.9]), GCTTS (9.1 [3.0], 4.0 [1.2]), or diffuse PVNS (14.5, 7.1) subtypes. Of 29 comparison PET/CTs in 6 patients, 17 were performed after nontargeted chemotherapy and 12 without antecedent therapy. Significant SUVr fluctuations (>25%) occurred in 11 cases; no correlation existed between SUVr change and presence or absence of chemotherapy. Conclusions Pigmented villonodular synovitis and GCTTS can be intensely hypermetabolic, mimicking musculoskeletal metastases on 18F-FDG PET/CT. They may have significant SUV fluctuations, both during nontargeted chemotherapy and between treatments. The diagnosis of PVNS/GCTTS should be considered for focal intra-articular or juxta-articular FDG-avid lesions, and MRI is useful in further evaluation given the often diagnostic imaging features with this modality.

KW - giant cell tumor of the tendon sheath

KW - PET/CT

KW - PVNS

KW - tenosynovial giant cell tumor

UR - http://www.scopus.com/inward/record.url?scp=84951127091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951127091&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000893

DO - 10.1097/RLU.0000000000000893

M3 - Article

C2 - 26164181

AN - SCOPUS:84951127091

VL - 41

SP - e24-e31

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 1

ER -